In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.
|Articles|June 1, 1999
Oncology NEWS International
- Oncology NEWS International Vol 8 No 6
- Volume 8
- Issue 6
Mayo Clinic Study Supports PSA Screening
DALLAS-Of 1,371 men with early-stage prostate cancer (T1c) detected by PSA screening and treated via radical prostatectomy between 1987 and 1996, only three have died of their cancer, Angelo J. Iocca, MD, of the Mayo Clinic, Rochester, Minnesota, said at the American Urological Society annual meeting.
Advertisement
DALLASOf 1,371 men with early-stage prostate cancer (T1c) detected by PSA screening and treated via radical prostatectomy between 1987 and 1996, only three have died of their cancer, Angelo J. Iocca, MD, of the Mayo Clinic, Rochester, Minnesota, said at the American Urological Society annual meeting.
Ten-year local recurrence-free survival, systemic progression-free survival, and systemic/local and/or PSA progression-free survival rates were 96.4%, 99%, and 74.8%, respectively. The findings provide indirect evidence in support of PSA screening as recommended by the AUA and American Cancer Society, he said.
Articles in this issue
over 27 years ago
Opioids Are Often Ignored for Treating Neuropathic Painover 27 years ago
Study Suggests Short Time Interval for Ovarian Cancer Screeningover 27 years ago
Your Strengths, Market’s Demands Dictate Marketing Strategiesover 27 years ago
First-Line Irinotecan Effective in Advanced Colorectal Cancerover 27 years ago
Doctor Ponders Popularity of Alternative Medicineover 27 years ago
Can Physicians Be Held Liable for Alternative Medicine?over 27 years ago
Tips on Marketing Your Oncology Practice to Patientsover 27 years ago
Biologics Research Promises ‘Synergistic’ Cancer Therapyover 27 years ago
Patient Care Costs of Clinical Trials May Be Less Than Standard Careover 27 years ago
Sentinal Node Biopsy Finds 98% of Metastic Colon CancersAdvertisement
Related to this article
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
3
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
4
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
5